All In MedTech

FDA Clearance Tracker · P230009

Shield

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Jul 26, 2024 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jul 26, 2024

Approved

Time to decision

504 days

Received Mar 10, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P230009
Device name
Shield
Applicant location
Palo Alto, CA
Received
Mar 10, 2023
Decided
Jul 26, 2024
Decision
Approved
Supplements
17 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code PHP

FDA's approval statement

As written in FDA's record.

The Shield test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit. Shield is intended for colorectal cancer screening in individuals at average risk of the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PHP. The earliest in FDA's data is P130017, decided Aug 11, 2014.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Guardant Health, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.